UNFOLD Study Egypt

Besides its role in the prognostic assessment of breast cancer, accurate determination of HER2 status is critical for appropriate selection of eligible patients for targeted therapy. In 2018, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) had a revised guideline for HER2 testing in breast cancer. Breast cancers were traditionally classified as HER2-pos and HER2-neg. HER2-positive BCs are those with either IHC3+ -characterized as complete, intense circumferential membrane staining in \>10% of cells-, or equivocal IHC (i.e., IHC2+) -characterized as weak to moderate/complete membrane staining in \>10% of cells- and ISH+. While HER2-negative BCs were considered those with one of the following results: IHC0 (No staining or incomplete, faint/barely perceptible staining in ≤10% of cells), IHC1+ (No staining or incomplete, faint/barely perceptible staining in \>10% of cells), or IHC2+ and ISH-. Recently, the HER2 categorization of BC has been differentiated into 3 subgroups: those with no detectable IHC staining (referred to herein as HER2 null), those with detectable HER2 staining in less than 10% of tumor cells (referred to herein as IHC\>0\<1+), and those with IHC1+ or IHC2+/ISH- results (collectively referred to herein as HER2-low). Little is known about the prevalence and clinical implications of HER2-neg BC subgroups that express low levels of HER2; these cancers have traditionally not been considered as separate subgroups and consequently there has been a lack of HER2-directed treatment options for these patients. Treatment options for mBC depend on several factors including, but not limited to, the patient's overall health and the levels of hormone receptor (HR) and HER2 in the tumor. Current SoC that is based on HER2 expression only considers BCs as being either HER2-pos or HER2-neg. For HER2-pos cancers, therapies that target HER2 combined with chemotherapy or other anti-HER2 agents can significantly improve survival. Although there are no therapies specifically for patients with HER2-low BC, preliminary evidence has demonstrated antitumor activity of T-DXd, an anti-HER2 agent, in HER2-low BCs. Hence, applying the most recent cut-off values when testing for HER2 expression is critical for maximizing treatment benefit for the highest number of patients (HER2-low \& HER2-pos). This national, multicenter, non-interventional, secondary data collection, retrospective study aims to describe the prevalence of HER2-low BC in Egypt by accurate categorization of HER2 status in HER2 reports of patients previously determined as HER2-neg and analyzing the SoC and clinical outcomes of HER2-low patients from medical chart abstraction.